Cardiopoietic index predicts heart repair fitness of patient-derived stem cells

Biomarkers in Medicine

Volumn 9, Issue 7, 2015, Pages 639-649

  Crespo Diaz, Ruben ^a   Yamada, Satsuki ^a   Bartunek, Jozef ^b   Perez Terzic, Carmen ^a,c   De Waele, Peter ^d   Mauën, Sébastien ^d   Terzic, Andre ^a   Behfar, Atta ^a  

^a Mayo Clinic   (United States)

^b OLV HOSPITAL   (Belgium)

^c MAYO CLINIC   (United States)

^d CELYAD   (Belgium)

Author keywords

cardiopoiesis; cardiopoietic stem cells; heart failure; mesenchymal; regenerative medicine; stem cells

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CD14 ANTIGEN; CD45 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOGLIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; THY 1 ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOG1; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR MEF2C; TRANSCRIPTION FACTOR MESP1; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIAC STEM CELL; CARDIOPOIESIS; CARDIOPOIETIC INDEX; CARDIOPOIETIC STEM CELL; CD34 SELECTION; CELL ISOLATION; CELL REGENERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ELECTRON MICROSCOPY; FEMALE; FITNESS; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; UPREGULATION; VERY ELDERLY; ANIMAL; BONE MARROW CELL; CYTOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; NUDE MOUSE; PATHOLOGY; STEM CELL; XENOGRAFT;

AGED; ANIMALS; BIOMARKERS; BONE MARROW CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84946554654     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.31     Document Type: Article

References (26)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 129(3), e28-e292 (2014
2. Kovacic JC, Fuster V. From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020. Clin. Pharmacol. Ther. 90(4), 509-518 (2011
3. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair - lessons from clinical trials. Nat. Rev. Cardiol. 11(4), 232-246 (2014
4. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 61(23), 2329-2338 (2013
5. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised Phase 1 trial. Lancet. 379(9819), 895-904 (2012
6. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 308(22), 2369-2379 (2012
7. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised Phase 1 trial. Lancet. 378(9806), 1847-1857 (2011
8. Schutt RC, Trachtenberg BH, Cooke JP, et al. Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. Circ. Res. 116(1), 99-107 (2015
9. Golpanian S, El-Khorazaty J, Mendizabal A, et al. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. J. Am. Coll. Cardiol. 65(2), 125-132 (2015
10. Behfar A, Terzic A. Stem cells versus senescence: the yin and yang of cardiac health. J. Am. Coll. Cardiol. 65(2), 148-150 (2015
11. Behfar A, Yamada S, Crespo-Diaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J. Am. Coll. Cardiol. 56(9), 721-734 (2010
12. Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature. 485(7400), 593-598 (2012
13. Behfar A, Perez-Terzic C, Faustino RS, et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J. Exp. Med. 204(2), 405-420 (2007
14. Yamada S, Arrell DK, Kane GC, et al. Mechanical dyssynchrony precedes QRS widening in ATP-sensitive K+ channel-deficient dilated cardiomyopathy. J. Am. Heart Assoc. 2(6), e000410 (2013
15. Behfar A, Terzic A. Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny. Nat. Clin. Pract. Cardiovasc. Med. 3(Suppl. 1), S78-S82 (2006
16. Behfar A, Crespo-Diaz R, Nelson TJ, Terzic A, Gersh BJ. Stem cells: clinical trials results the end of the beginning or the beginning of the end Cardiovasc. Hematol. Disord. Drug Targets. 10(3), 186-201 (2010
17. Cogle CR, Wise E, Meacham AM, et al. Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ. Res. 115(10), 867-874 (2014
18. Behfar A, Terzic A. Stem cell in the rough: repair quotient mined out of a bone marrow niche. Circ. Res. 115(10), 814-816 (2014
19. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J. 28(6), 766-772 (2007
20. Hansson EM, Lindsay ME, Chien KR. Regeneration next: toward heart stem cell therapeutics. Cell Stem Cell. 5(4), 364-377 (2009
21. Behfar A, Yamada S, Crespo-Diaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J. Am. Coll. Cardiol. 56(9), 721-734 (2010
22. Hahn JY, Cho HJ, Kang HJ, et al. Pre-Treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J. Am. Coll. Cardiol. 51(9), 933-943 (2008
23. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst. Rev. 2, CD006536 (2012
24. Loffredo FS, Steinhauser ML, Gannon J, Lee RT. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell. 8(4), 389-398 (2011
25. Smart N, Riley PR. The stem cell movement. Circ. Res. 102(10), 1155-1168 (2008
26. Crespo-Diaz R, Behfar A, Butler GW, et al. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant. 20(6), 797-811 (2011